| 货号 | AF144-SP |
| 别名 | BM-018; CD358 antigen; CD358; Death receptor 6; DR6TNFR-related death receptor 6; MGC31965; TNFRSF21; tumor necrosis factor receptor superfamily member 21; tumor necrosis factor receptor superfamily, member 21 | 全称 | Death Receptor 6 |
| 反应种属 | Human |
| 应用 | Western Blot(0.1 µg/mL) ELISA Capture (Matched Antibody Pair)(0.2-0.8 µg/mL ) ELISA Detection (Matched Antibody Pair)(0.1-0.4 µg/mL ) ELISA Standard ( ) |
| 目标/特异性 | Detects human DR6 in ELISAs and Western blots. In sandwich ELISAs, less than 0.2% cross-reactivity with recombinant human (rh) OPG and rhTNF RII is observed. |
| 使用方法 | Western Blot: 0.1 µg/mL ELISA Capture (Matched Antibody Pair): 0.2-0.8 µg/mL ELISA Detection (Matched Antibody Pair): 0.1-0.4 µg/mL ELISA Standard : |
| 来源 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 产品组分 |
| 供应商 | R&D Systems |
| Entrez Gene IDs | 27242 (Human); 94185 (Mouse); 316256 (Rat) |
| 应用文献 | |
| R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP. | |
| 纯化方式 | Antigen Affinity-purified |
| 免疫原 | Mouse myeloma cell line NS0-derived recombinant human DR6 Gln42-Leu350 Accession # O75509 |
| 生物活性 | Human |
| 标记 | Unconjugated |
| 溶解方法 | Reconstitute at 0.2 mg/mL in sterile PBS. |
| 背景 | Death Receptor 6 (DR6), also known as TNFRSF21 and CD358, is a type I transmembrane protein in the TNF receptor superfamily (1). Human DR6 consists of a 308 amino acid (aa) extracellular domain (ECD) with four cysteine‑rich motifs, a 21 aa transmembrane segment, and a 285 aa palmitylated cytoplasmic region that contains one death domain (2, 3). Within the ECD, human and mouse DR6 share 82% aa sequence identity. DR6 is expressed as an approximately 110 kDa molecule that carries extensive N‑linked and O‑linked glycosylation in its extracellular region (3, 4). Among hematopoietic cells, DR6 is expressed on monocytes, resting CD4+ T cells, and pro‑, pre‑, and naïve B cells (5 ‑ 7). DR6 knockout mice exhibit a Th2‑biased immune response characterized by exaggerated Th2 and B cell responsiveness in combination with reduced Th1 cell responsiveness and inflammatory leukocyte infiltration (6 ‑ 9). DR6 knockout mice are resistant to induced airway inflammation and experimental autoimmune encephalitis but more susceptible to severe graft versus host disease (9 ‑ 11). DR6 is also expressed on developing neurons where it can bind a shed 35 kDa N‑terminal fragment of APP or a fragment of APLP2 (12, 13). This APP fragment is generated following deprivation of neurotrophic factors, and its binding to DR6 triggers DR6‑mediated axonal pruning (12). DR6 is constitutively expressed on some prostate cancer cells and can be induced by TNF‑ alpha on others (3, 4). |
| 运输条件 | Blue Ice |
| 存放说明 | 4℃ |
| 参考文献 |
|